Recombinant AAV vectors mediate efficient and sustained transgene expression in retinal tissues and offer a powerful approach to the local, sustained delivery of angiostatic proteins for the treatment of ocular neovascular disorders.
Introduction
Neovascularization of the retina and choroid is a central feature of diabetic retinopathy and age-related macular degeneration, respectively. These conditions are leading causes of blindness in developed countries 1, 2 for which current treatments are of limited efficacy and associated with significant adverse effects. 3, 4 Advances in the understanding of the molecular basis of angiogenesis have identified targets for rationally designed novel therapies including the proangiogenic mediator vascular endothelial growth factor (VEGF) 5 and the angiogenesis inhibitor pigment epithelium-derived growth factor (PEDF). 6 Transfer of genes encoding therapeutic molecules to the retina offers the possibility of local sustained delivery following a single procedure. Recombinant adeno-associated virus (rAAV) and lentivirus vectors are particularly attractive because of their ability to mediate efficient, sustained transgene expression in retinal cells. 7, 8 We have previously shown that inhibition of VEGF by local gene transfer of its soluble receptor sFlt-1 controls retinal neovascularization in a murine model of ischaemic retinopathy. 9 Others have described suppression of experimental choroidal neovascularization in rodent models by local gene transfer of sFlt-1, 10 pigmentepithelium-derived factor 11, 12 and angiostatin. 13 Many molecular mediators of angiogenesis, however, also mediate essential physiological functions in the retina. VEGF itself is believed to mediate important housekeeping functions in the mature retina and acts as a survival factor for vascular endothelium. 14 For this reason, the long-term uncontrolled inhibition of such mediators by the sustained and unregulated expression of angiostatic proteins presents a significant risk of adverse local effects. The development of strategies to achieve effective targeting of expression and to enable appropriate regulation of gene expression is therefore required to minimize the potential for local toxicity. One approach to regulation of gene expression is through the incorporation of inducible promoters responsive to the administration of exogenous pharmacological agents. Tetracycline-inducible systems, for example, can facilitate regulation of gene expression in the retina using adenoviral 15 or rAAV 16 vectors. Intraocular expression following rAAV-mediated transduction may similarly be regulated by rapamycin-inducible systems. 17 These pharmacological approaches are dependent, however, on regular clinical observation to determine appropriate dosing and may be limited by inefficient drug penetration across the blood-retinal barrier. An alternative approach is to couple transgene expression to changes in the local tissue environment. Since retinal neovascularization is typically the result of local tissue hypoxia, we were interested to investigate the possibility of hypoxia-regulated expression of angiostatic molecules. The synthetic hypoxia-responsive element OBHRE combines low basal expression in normoxic conditions with high-level activated expression when the oxygen con-centration is low. 18 In this study, we have evaluated in vivo the targeting and kinetics of HRE-driven rAAVmediated reporter gene expression in murine models of retinal and choroidal neovascularization.
A recombinant AAV (serotype 2) vector encoding the GFP gene under the control of the HRE promoter was constructed. The GFP cDNA was removed from pd2EGFP-1 (BD Biosciences Clontech UK, Oxford) as a SmaI-XbaI fragment. This was blunt cloned into the HindIII-XbaI sites of OBHRE pGL3 plasmid 18 to replace the luciferase gene and create pOBHRE.GFP. The BlnIHpaI GFP containing fragment from pOBHRE-GFP was cloned in place of the mEPO gene in AAV.HRE.Epo 19 to create the AAV.HRE.GFP plasmid. Recombinant AAV vectors (serotype 2) were produced using the replicating amplicon system described previously 20 with a slight modification in the purification procedure: the CsCl gradient purification step was replaced with an iodoxianol gradient followed by a one-step affinity purification procedure on a heparin column. 21 AAV particles were determined by dot-blot quantification of genome copy and direct comparison to a recombinant AAV vector expressing CMV.GFP of known biological titre. Vector suspensions of comparable titre (1 Â 10 11 particles/ml) were used for all intraocular injections.
We first evaluated HRE-driven reporter gene expression after intravitreal vector delivery in a well-characterized murine model of ischaemia-induced VEGFdependent retinal neovascularization. 22 Exposure of newborn mice to 75% oxygen from p7 to p12 results in retinal capillary obliteration at the posterior pole and preretinal neovascularization, which reaches its greatest extent from p17 to p21 and thereafter undergoes gradual spontaneous resolution. 22 In order to determine the pattern of HRE-driven transgene expression following intraocular administration of rAAV vectors in this model, we compared GFP reporter gene expression after intravitreous injection of vectors in which transgene expression was driven by either HRE or CMV promoters. To compensate for the expected delay in transgene expression 23 and achieve established expression by the time of onset of active angiogenesis in this model (postnatal days p12-p19) we injected the rAAV vector at p2. We enucleated and analysed the eyes for vectormediated expression at p19 during the peak of ischaemia-induced retinal neovascularization, and at p34 by which point a more normal vascular architecture is restored. 22 After induction of retinal ischaemia, CMVdriven reporter gene expression at p19 was evident in cells widely distributed across the retina (Figure 1a ), in the ganglion cell layer, inner nuclear and the outer nuclear layers (Figure 2a ). At p34 CMV-driven expression was sustained across the retina (Figures 1b  and 2b ). In age-matched control mice without retinal ischaemia, CMV-driven expression was similarly HRE-driven expression in normal control at p34. In order to illustrate the typical pattern of retinal vascular nonperfusion in this model, fluorescent micrographs of retinal flatmounts from uninjected normal (i) and ischaemic (j) retinas following terminal perfusion with fluoresceinconjugated dextran at p19 are included. Retinal nonperfusion is evident as hypofluorescent areas devoid of normal retinal capillary network (white arrows). Litters of C57Bl/6J mice (Harlan, UK) were used. All animals were treated in a humane manner and were managed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Retinal ischaemia was induced in mice as described elsewhere. 22 Briefly, ischaemic retinopathy was induced by exposure of mouse pups to 7573% oxygen from p7 to p12 in a sealed incubator along with nursing mothers. Age-matched control animals were raised in room air throughout. Eyes of mice raised in hyperoxia and control animals raised in room air were injected intravitreally with AAV.HRE.GFP (n¼15), injected with AAV.CMV.GFP (n¼15) or were uninjected (n¼8). To compensate for the delay in AAV-mediated expression intravitreal injections were performed at p2. The injection procedure was performed as previously described. 9 Approximately 1 ml of viral suspension was injected into the vitreous cavity in each case. Animals were killed for analysis at either p19 or p34 by cervical dislocation. Analysis of GFP reporter gene expression was performed in whole-mounted retinas. Enucleated eyes were fixed in 4% paraformaldehyde for 1 h and retinal whole-mounts were prepared. The cornea and lens were removed and the retina dissected from the eyecup. The retina was cut radially into four quadrants and flat-mounted in Aquamount under a coverslip for examination by fluorescence microscopy. In retinal flat-mounts GFP expression is evident as bright granular green fluorescence on a background of diffuse green auto-fluorescence of photoreceptor cells. (Figures 1c and 2c ) and sustained ( Figures  1d and 2d) . In contrast, in mice with retinal ischaemia, HRE-driven reporter gene expression at p19 was restricted to areas at the posterior pole ( Figure 1e ) in a configuration consistent with the typical pattern of retinal capillary nonperfusion in this model (Figure 1j ). GFP expression was observed in the ganglion cell layer, inner nuclear and the outer nuclear layers (Figure 2e) . At a later time point (p34) in animals previously exposed to hyperoxia, HRE-driven GFP expression was observed only in occasional cells (Figures 1f and 2f) . In agematched control animals without retinal ischaemia HREdriven expression was not observed at either time point (Figure 1g , h, 2g, h). We next investigated HRE-driven expression after subretinal vector delivery in a murine model of laserinduced choroidal neovascularization. 24 Laser-induced rupture of Bruch's membrane results in the growth of new vessels that extend into the subretinal space from the choroid. The neovascular response following laser rupture evolves during the first 2 weeks after and thereafter is nonprogressive or gradually regresses. 25 In order to determine the pattern of HRE-driven transgene expression in this model, we compared GFP reporter gene expression after subretinal delivery of vectors driven by HRE and CMV promoters. To compensate for the expected delay in transgene expression and achieve established expression during the period of active angiogenesis in this model (the first 2 weeks after laser induction), we delivered the vector 4 weeks in advance of laser rupture. We analysed the eyes for vector-mediated expression immediately prior to laser rupture, 7 days after laser rupture during the period of active neovascularization, and at 28 days when choroidal neovascularization is believed to be no longer active. Laser injury resulted in the presence of a limited amount of autofluorescent debris in the subretinal space regardless of vector delivery (Figure 3b, c) . After subretinal delivery of rAAV, CMV-driven expression was observed in photoreceptor cells prior to laser injury (Figure 3d ), 7 days after laser injury (Figure 3e ) and was sustained at 28 days (Figure 3f ). GFP expression was widely distributed across the retina at sites of laser rupture (Figure 3e ) and elsewhere. In contrast, significant HREdriven GFP expression was evident only at sites of laser rupture and was not sustained over time. Prior to laser injury HRE-driven expression was evident in only occasional photoreceptors (Figure 3g ). At 7 days after laser injury HRE-driven expression was seen in significant numbers of cells overlying the site of laser injury (Figure 3h ) but not elsewhere. After 28 days, HREdriven expression was observed only in occasional photoreceptors even at the site of laser rupture (Figure 3i) .
In this study, we demonstrate that HRE-driven rAAVmediated transgene expression in vivo specifically targets experimental retinal and choroidal neovascularization both spatially and temporally. Hypoxia-inducible factor-1 (HIF-1) is a transcription factor composed of two basic helix-loop-helix PAS-proteins: HIF-1 beta/ARNT (aryl hydrocarbon receptor nuclear translocator), which is constitutively expressed, and HIF-1 alpha, which is degraded by the ubiquitin-proteasome system in normoxia, but stabilized under hypoxic conditions. HIF-1 mediates transcriptional responses to hypoxia by binding to an HRE that is a highly conserved cis-acting specific enhancer present in a number of genes including those encoding VEGF, erythropoietin and inducible nitric oxide synthase. 26 The incorporation of an HRE into promoter sequences of therapeutic constructs results in the regulation of transgene expression in response to hypoxia. This approach is currently being pursued in the design of vectors for hypoxia-targeted delivery in several contexts. Hypoxia-inducible vectors are of potential value for tumour-targeting in cancer gene therapy. [27] [28] [29] Similar systems have been described to automatically upregulate expression of cardioprotective transgenes in HRE-driven expression targets ocular neovascularization JWB Bainbridge et al myocardial ischaemia 30, 31 and to achieve physiological regulation of erythropoietin expression to appropriately correct anaemia in a rodent model of erythropoietin deficiency. 19 In both models described in the present study, progression of neovascularization occurs in response to a single event and is relatively short lived in duration. While the self-limiting course is dissimilar to retinal and choroidal neovascularization in human disorders that tend to follow a more prolongued course, in the present study the transient course enabled the investigation of HRE-driven expression in response to changes in hypoxia over time. In ischaemia-induced retinal neovascularization CMV-driven expression was observed across a wide area of the retina and was sustained over time. In contrast, HRE-driven expression was evident only at the posterior pole and was not sustained: a pattern consistent with the temporal and spatial features of retinal capillary nonperfusion and hypoxia-driven upregulation of VEGF, which are well described in this model. 22, 32 Following laser rupture of Bruch's membrane, CMVdriven GFP expression was seen ubiquitously in photoreceptor cells and retinal pigment epithelial cells regardless of the timing or site of laser rupture. HRE-driven expression however was restricted to photoreceptor cells overlying the developing choroidal neovascular complex; expression was not significant prior to laser rupture Choroidal neovascularization was induced in adult mice by laser rupture of Bruch's membrane. Adult C57Bl/6J mice were anaesthetized with intraperitoneal injection of 0.2 ml Hypnorm (Janssen Pharmaceutical Ltd, Oxford, UK), and Hypnovel (Roche, Welwyn Garden City, UK) mixed 1:1:6 with distilled water. Animals underwent retinal photocoagulation (200 mW, 100 mm spot size, 100 ms) at four sites around the optic disc at the posterior pole by means of a slit-lamp mounted diode laser to induce formation of an air bubble and an immediate chalk-white blanching of the retina. Age-matched control animals received no laser injury. Eyes of mice in which choroidal neovascularization was induced by laser injury and unlasered control eyes underwent subretinal injections of AAV.HRE.GFP (n¼12), AAV.CMV.GFP (n¼12) or were uninjected (n¼6). To compensate for the delay in rAAV-mediated expression, vector delivery was performed 4 weeks prior to laser injury. The subretinal injection procedure was performed as previously described. 8 Approximately 2 ml of the vector suspension was injected into the subretinal space. For each eye, the procedure was repeated at a second site opposite to the original injection site in order to maximize the area of retinal transduction. Mice were killed by cervical dislocation and enucleated for analysis 4 weeks after vector delivery, 7 days after laser injury or 28 days after laser injury. Analysis of GFP reporter gene expression was performed in cryosections as described in the legend of Figure 2 .
HRE-driven expression targets ocular neovascularization JWB Bainbridge et al and was not sustained after 4 weeks even at the site of laser rupture. Though laser rupture resulted in a limited amount of autofluorescent material in the subretinal space regardless of vector delivery, HRE-driven GFP expression was also observed in RPE cells specifically at sites of laser injury. HRE-driven expression in this model is consistent with a possible role for hypoxia in the evolution of choroidal neovascularization following laser rupture of Bruch's membrane. Alternative mechanisms may however be involved. HREs may be activated by transcription factors other than HIF-1 33 and it is possible that HRE-driven expression may occur as part of a stress or wound-healing response in the context of laser injury. Although upregulation of VEGF expression is well described in laser-induced choroidal neovascularization, [34] [35] [36] peaking at up to 7 days after wounding, 25 retinal VEGF expression may also be upregulated in conditions other than ischaemia 37 and may not be dependent on hypoxia-induced activation of HIF-1. Whichever is the case in this experimental model, a role for ischaemia has been implicated in the pathogenesis of choroidal neovascularization in human patients 38 and there is good reason to believe that HRE-driven expression may facilitate the effective targeting of angiogenesis in the clinical context.
In both models, the incorporation of an HRE into the promoter sequence targets gene expression to sites of neovascularization and results in expression that is not sustained beyond the period of active angiogenesis. This hypoxia-inducible system offers a powerful means to achieve spatial and temporal regulation of expression of angiostatic proteins in the management of retinal and choroidal neovascularization by gene transfer. In this way sites of active neovascularization may be effectively targeted, while minimizing inappropriate expression elsewhere or during periods of angiogenic inactivity. This approach offers a vigilant system in which HREdriven expression is likely to anticipate the onset of a neovascular response to ischaemia in a way not possible with pharmacologically inducible systems in which dosing is dependent on the clinical observation of established new vessels. This strategy also offers the possibility of disease-related dosing in which the level of HRE-driven expression is continuously adjusted in response to changes in tissue oxygenation such that it is directly correlated to the intensity of angiogenic drive.
